Replies to post #242414 on Biotech Values

[DewDiligence]

PFE-BHVN correction—#msg-168806558 mistakenly says that shareholders of “both companies” will receive 0.5 shares of a newly formed (as yet unnamed) company that will retain BHVN’s non-migraine, early-stage pipeline. In fact, only BHVN shareholders will receive shares of this new company. PFE itself (a 3% owner of BHVN prior to the buyout deal) will get shares of this newly formed company, but PFE’s shareholders will not.

[DewDiligence]

PFE-BHVN CC slides:

https://s28.q4cdn.com/781576035/files/doc_downloads/2022/05/Biohaven-Investor-Slides_FINAL.pdf

[WorstLuck]

BHVN

Sheep of Wall Street
@Biohazard3737
Hope Favus' track record holds with $BHVN.

Remember his calls on $GWPH and $IMMU very well before they were acquired at unbelievable premiums.
10:25 AM · Apr 28, 2022·Twitter Web App

[DewDiligence]

BHVN’s Nurtec 2Q22 sales=$194M, +57% QoQ:

https://www.prnewswire.com/news-releases/biohaven-reports-second-quarter-2022-financial-results-and-reports-recent-business-developments-301600624.html

The acquisition by PFE is expected to close in early 2023.

[DewDiligence]

PFE—FDA approves Zavzpret—(zavegepant)—nasal spray for acute migraine:

https://www.businesswire.com/news/home/20230309005795/en

Zavzpret is the “other” asset PFE obtained in the $11.6B buyout of BHVN in 2022 (#msg-168806558).

Between Nurtec and Zavzpret, PFE projects $6B in peak annual sales for the migraine franchise, according to PFE’s Investor Day in Dec 2022 (https://investors.pfizer.com/files/doc_presentation/2022/12/B/Pfizer-Near-Term-Launches-High-Value-Pipeline-Day-Presentation_1245pm_v2.pdf, slides 12-24).

[DewDiligence]

LLY fails_to_show Emgality superiority_to PFE’s Nurtec in_phase-4_trial in prevention of episodic migraine:

https://finance.yahoo.com/news/first-kind-head-head-clinical-160000632.html

https://finance.yahoo.com/news/1-eli-lillys-migraine-drug-162030131.html

This trial was a calculated gamble by LLY to slow down the commercial uptake of PFE’s Nurtec, which has been outselling Emgality despite Nurtec’s coming to market later.

p.s. Between Nurtec and Zavzpret, PFE forecasts peak annual migraine sales of $6B (#msg-171411588).